Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for GSK plc (GSK) provides access to the company’s regulatory disclosures as a foreign private issuer. GSK files an annual report on Form 20-F and frequent current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with information on American Depositary Shares listed on the New York Stock Exchange, form a key source of official information for investors analyzing GSK stock.
Recent Form 6-K filings include multiple transaction notifications for persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These reports detail acquisitions of ordinary shares or American Depositary Shares, often through dividend reinvestment plans, share reward plans or the exercise of options under GSK’s share save arrangements, and specify trade dates, prices, volumes and trading venues such as the London Stock Exchange and New York Stock Exchange.
Other 6-K filings report total voting rights, including the number of issued ordinary shares, treasury shares and the resulting total voting rights figure. This information helps shareholders determine whether they must notify changes in their holdings under applicable disclosure rules. Additional 6-K submissions incorporate press releases on significant product approvals, clinical trial results and agreements, such as approvals for Exdensur (depemokimab), Nucala (mepolizumab) in COPD, Shingrix prefilled syringe presentations, and positive phase III results for bepirovirsen in chronic hepatitis B.
On Stock Titan, these filings are complemented by AI-powered summaries that explain the practical meaning of each document. Investors can quickly understand insider dealing reports, changes in capital structure, and major regulatory or clinical events without reading every line of the original filing. Real-time updates from EDGAR ensure that new GSK 6-K submissions, as well as the annual 20-F, appear promptly, while insider transactions analogous to Form 4 in the US domestic context are captured through the PDMR transaction notifications.
By using this page, users can review GSK’s historical and current SEC filings, track patterns in executive and director share dealings, and connect clinical and regulatory announcements to their formal disclosure record, all with the support of AI-generated explanations.
GSK has reported a significant share buyback transaction on June 26, 2025. The company purchased 485,032 ordinary shares through Merrill Lynch International at prices ranging from 1,390.00p to 1,405.00p per share, with a volume-weighted average price of 1,397.83p.
Key transaction details:
- All purchases were executed on the London Stock Exchange (XLON)
- Following this purchase, GSK holds 225,206,623 shares in treasury
- Total voting rights now stand at 4,090,138,849
- Treasury shares represent 5.51% of voting rights
This purchase is part of GSK's ongoing buyback programme announced on June 4, 2025, under which the company has acquired 7,072,240 ordinary shares to date. The transaction demonstrates GSK's continued commitment to returning value to shareholders through its share repurchase strategy.
GSK has reported a significant share buyback transaction on June 25, 2025. The company purchased 483,629 ordinary shares at prices ranging from 1,395.00p to 1,411.00p per share, with a volume-weighted average price of 1,400.74p.
Key transaction details:
- All trades were executed on the London Stock Exchange (XLON)
- Following this purchase, GSK holds 224,721,591 shares in treasury
- Total voting rights now stand at 4,090,623,881
- Treasury shares represent 5.49% of voting rights
This purchase is part of GSK's existing buyback program announced on June 4, 2025. Since the program's inception, the company has purchased 6,587,208 ordinary shares, demonstrating significant progress in their capital return strategy.
GSK plc reports a significant share buyback transaction on June 24, 2025. The company purchased 476,537 ordinary shares at prices ranging from 1,403.50p to 1,421.50p per share, with a volume-weighted average price of 1,411.62p.
Key transaction details:
- All trades executed on London Stock Exchange (XLON)
- Part of existing buyback program announced June 4, 2025
- Total shares purchased since program inception: 6,103,579
- Post-transaction treasury holdings: 224,237,962 shares
- Total voting rights: 4,091,107,510
- Treasury shares represent 5.48% of voting rights
The transaction demonstrates GSK's ongoing commitment to returning value to shareholders through its share repurchase program.
GSK has reported multiple share transactions by Sally Jackson, SVP of Global Communications & CEO Office, and her associated person Dylan Jackson on June 19, 2025. The transactions include:
- Sally Jackson gifted 1,400 ordinary shares to a family member at nil consideration
- Sally Jackson sold 1,395 shares at £14.3524 and purchased 1,387 shares at £14.3378 as part of an ISA transfer
- Dylan Jackson (PCA) sold 1,395 shares at £14.3524 and purchased 1,385 shares at £14.3537 as part of an ISA transfer
All transactions were conducted on the London Stock Exchange. These share movements represent portfolio restructuring into Individual Savings Accounts (ISAs) rather than significant changes in ownership positions. The transactions were reported in compliance with regulatory requirements for PDMRs (Persons Discharging Managerial Responsibilities) and their closely associated persons.
GSK announced a significant board-level change at one of its Non-Executive Directors' external commitments. Wendy Becker, who serves as GSK's Non-Executive Director and Chair of the Remuneration Committee, has been appointed as Chair of the Board of Sony Group Corporation, effective June 24, 2025. This represents a promotion from her previous position as Vice Chair of Sony's Board.
This disclosure, filed as a Form 6-K (foreign issuer report), reflects GSK's commitment to transparency regarding its directors' external appointments and potential commitments. The appointment was officially documented by Victoria Whyte, GSK's Company Secretary.
- Filing Date: June 28, 2025
- Effective Date of Appointment: June 24, 2025
- Key Personnel: Wendy Becker (Non-Executive Director)
- New Role: Chair of Sony Group Corporation Board
- Previous Role at Sony: Vice Chair of the Board
GSK has reported a significant share buyback transaction on June 23, 2025. The company purchased 483,823 ordinary shares through Merrill Lynch International at prices ranging from 1,398.00p to 1,414.50p per share, with a volume-weighted average price of 1,403.43p.
Key transaction details:
- All trades were executed on the London Stock Exchange (XLON)
- Following this purchase, GSK holds 223,761,425 shares in treasury
- Total voting rights now stand at 4,091,584,047
- Treasury shares represent 5.47% of voting rights
This purchase is part of GSK's existing buyback program announced on June 4, 2025. Since the program's inception, the company has purchased 5,627,042 ordinary shares, demonstrating significant progress in their capital return strategy.
GSK announced that the European Medicines Agency (EMA) has accepted for review the marketing authorization application for linerixibat, a targeted inhibitor of the ileal bile acid transporter (IBAT), for treating cholestatic pruritus in patients with primary biliary cholangitis (PBC).
Key highlights:
- The application is based on positive results from the GLISTEN phase III trial, which met both primary and secondary endpoints
- Linerixibat demonstrated rapid, significant, and sustained improvement in cholestatic pruritus and itch-related sleep interference versus placebo
- The drug addresses an unmet medical need, as up to 90% of PBC patients experience pruritus, with current first-line treatments not reducing its severity
- The trial involved 238 PBC patients across 19 countries, marking it as the first truly global PBC study
This EMA acceptance follows FDA acceptance earlier in the month. Linerixibat has received orphan drug designation from both FDA and EMA, and is currently under review in the US and UK markets.